• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高剂量万古霉素治疗感染的综述。

Review of high dose vancomycin in the treatment of infection.

作者信息

Bader Mazen S, Hawboldt John, Main Cheryl, Mertz Dominik, Loeb Mark, Farrell Alison, Joyce Joanna

机构信息

Faculty of Health Sciences, Department of Medicine, Division of Infectious Diseases, McMaster University, Hamilton, Canada.

Hamilton Health Sciences, Juravinski Hospital and Cancer Centre, Hamilton, Canada.

出版信息

Infect Dis (Lond). 2020 Nov-Dec;52(12):847-857. doi: 10.1080/23744235.2020.1800080. Epub 2020 Aug 3.

DOI:10.1080/23744235.2020.1800080
PMID:32744879
Abstract

BACKGROUND

Guidelines recommend oral vancomycin as first-line therapy for infection. Guideline recommendations vary regarding dosing of vancomycin. Our aim was to summarize the current evidence on the efficacy and adverse effects of high dose oral and vancomycin retention enema (>500 mg/day) for the treatment of infection.

METHODS

We searched clinical studies and major guidelines in the English language using MEDLINE, the Cochrane Library and Embase from 1985 until 15 April 2020.

RESULTS

No evidence supports the use of high dose oral vancomycin in the treatment of severe infection. Weak evidence from observational studies supports the use of high dose oral vancomycin in addition to intravenous metronidazole and high dose vancomycin retention enema in fulminant infection. Vancomycin retention enema can be used in severe infection when oral administration is not possible, or in conditions when the oral formulation cannot reach the colon such as Hartman's pouch, ileostomies, or colon diversions.

CONCLUSIONS

The dosing schedules for oral vancomycin and vancomycin enemas are not clearly defined due to widely varying results in clinical studies. Large, comparative multicenter trials are urgently needed to define the role of high dose vancomycin in infection.

摘要

背景

指南推荐口服万古霉素作为[感染名称]感染的一线治疗药物。关于万古霉素的给药剂量,指南建议各不相同。我们的目的是总结目前关于高剂量口服万古霉素和万古霉素保留灌肠(>500mg/天)治疗[感染名称]感染的疗效和不良反应的证据。

方法

我们使用MEDLINE、Cochrane图书馆和Embase从1985年至2020年4月15日检索了英文的临床研究和主要指南。

结果

没有证据支持使用高剂量口服万古霉素治疗严重[感染名称]感染。观察性研究的薄弱证据支持在暴发性[感染名称]感染中,除静脉注射甲硝唑外,加用高剂量口服万古霉素和高剂量万古霉素保留灌肠。当无法口服给药,或在口服制剂无法到达结肠的情况下,如哈特曼袋、回肠造口术或结肠改道时,万古霉素保留灌肠可用于严重[感染名称]感染。

结论

由于临床研究结果差异很大,口服万古霉素和万古霉素灌肠的给药方案尚未明确界定。迫切需要进行大规模、比较性的多中心试验来确定高剂量万古霉素在[感染名称]感染中的作用。

相似文献

1
Review of high dose vancomycin in the treatment of infection.高剂量万古霉素治疗感染的综述。
Infect Dis (Lond). 2020 Nov-Dec;52(12):847-857. doi: 10.1080/23744235.2020.1800080. Epub 2020 Aug 3.
2
Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?静脉注射甲硝唑是否能改善艰难梭菌感染的疗效?
Clin Infect Dis. 2020 Dec 3;71(9):2414-2420. doi: 10.1093/cid/ciz1115.
3
Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.口服万古霉素治疗艰难梭菌感染与万古霉素耐药肠球菌风险。
Clin Infect Dis. 2020 Jul 27;71(3):645-651. doi: 10.1093/cid/ciz871.
4
Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Infection: A Systematic Review and Meta-Analysis.口服万古霉素治疗初发感染的有效剂量:一项系统评价与荟萃分析
Antibiotics (Basel). 2019 Oct 1;8(4):173. doi: 10.3390/antibiotics8040173.
5
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.与最近的指南建议去除甲硝唑治疗非严重艰难梭菌感染相关的结果:一项回顾性、观察性、全国性队列研究。
Int J Antimicrob Agents. 2021 Mar;57(3):106282. doi: 10.1016/j.ijantimicag.2021.106282. Epub 2021 Jan 17.
6
Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.口服甲硝唑、万古霉素和非达霉素对艰难梭菌宿主脱落和环境污染的影响。
Clin Infect Dis. 2022 Mar 1;74(4):648-656. doi: 10.1093/cid/ciab473.
7
Changes in Metronidazole and Vancomycin Utilization for Nonsevere Clostridioides difficile Infection Among Institutions Caring for Children.医疗机构中非重症艰难梭菌感染患者中甲硝唑和万古霉素使用情况的变化。
Pediatr Infect Dis J. 2021 Jul 1;40(7):634-636. doi: 10.1097/INF.0000000000003117.
8
A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.一项针对甲硝唑和万古霉素治疗艰难梭菌感染的荟萃分析,按疾病严重程度分层。
Braz J Infect Dis. 2015 Jul-Aug;19(4):339-49. doi: 10.1016/j.bjid.2015.03.006. Epub 2015 May 19.
9
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. fidaxomicin 与甲硝唑、万古霉素及其联合治疗首发、首次复发和严重艰难梭菌感染的疗效比较:一项观察性队列研究。
Int J Infect Dis. 2021 Feb;103:226-233. doi: 10.1016/j.ijid.2020.11.004. Epub 2020 Nov 11.
10
Critique of "Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection".《对“在非暴发性严重艰难梭菌感染的重症患者中,静脉注射甲硝唑联合口服万古霉素治疗的评估”的评论》
Pharmacotherapy. 2020 Sep;40(9):984. doi: 10.1002/phar.2455.